骨转换指标和骨密度监测治疗骨质疏松及其与骨折的关系

被引：23

作者：

伍西羽

伍贤平

廖二元

机构：

[1] 中南大学湘雅二医院内分泌科

来源：

中国骨质疏松杂志 | 2007年 / 11期

关键词：

骨转换指标; 骨密度; 骨质疏松; 骨折风险; 监测治疗;

D O I：

暂无

中图分类号：

R580 []; R683 [骨折、骨的损伤];

学科分类号：

100220 [骨科学];

摘要：

骨转换指标和骨密度(BMD)对监测治疗骨质疏松及预测骨折的风险具有重要的临床意义。本文扼要综述了骨转换指标和BMD在治疗骨质疏松中的监测频率和最小显著变化(LSC),以及两者与骨折风险的关系,它对于指导临床监测治疗骨质疏松具有重要价值。

引用

页码：797 / 802

页数：6

共 14 条

[1]

Serum concentrations of MMP-1; MMP-2; and TIMP-1 in Chinese women: Age-related changes; and the relationships with bone biochemical markers; bone mineral density.[J].Li-Juan Guo;Xiang-Hang Luo;Xian-Ping Wu;Peng-Fei Shan;Hong Zhang;Xing-Zhi Cao;Hui Xie;Er-Yuan Liao.Clinica Chimica Acta.2006, 1

[2]

Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both? [J].

Bonnick, SL ;

Shulman, L .

AMERICAN JOURNAL OF MEDICINE, 2006, 119 (04) :25S-31S

[3]

Minimum sample size requirements for bone density precision assessment produce inconsistency in clinical monitoring [J].

Leslie, W. D. ;

Moayyeri, A. .

OSTEOPOROSIS INTERNATIONAL, 2006, 17 (11) :1673-1680

[4]

Pi, Yin-Zhen ;

Wu, Xian-Ping ;

Liu, Shi-Ping ;

Luo, Xiang-Hang ;

Cao, Xing-Zhi ;

Xie, Hui ;

Liao, Er-Yuan .

JOURNAL OF BONE AND MINERAL METABOLISM, 2006, 24 (05) :380-385

[5]

Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004) [J].

Nishizawa, Y ;

Nakamura, T ;

Ohta, H ;

Kushida, K ;

Gorai, I ;

Shiraki, M ;

Fukunaga, M ;

Hosoi, T ;

Miki, T ;

Chaki, O ;

Ichimura, S ;

Nakatsuka, K ;

Miura, M .

JOURNAL OF BONE AND MINERAL METABOLISM, 2005, 23 (02) :97-104

[6]

Reproducibility of bone mineral density measurements using dual X-ray absorptiometry in daily clinical practice [J].

El Maghraoui, A ;

Zounon, AAD ;

Jroundi, I ;

Nouijai, A ;

Ghazi, M ;

Achemlal, L ;

Bezza, A ;

Tazi, MA ;

Abouqual, R .

OSTEOPOROSIS INTERNATIONAL, 2005, 16 (12) :1742-1748

[7]

Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate:: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide [J].

Tähtelä, R ;

Seppänen, J ;

Laitinen, K ;

Katajamäki, A ;

Risteli, J ;

Välimäki, MJ .

OSTEOPOROSIS INTERNATIONAL, 2005, 16 (09) :1109-1116

[8]

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial [J].

Chapurlat, RD ;

Palermo, L ;

Ramsay, P ;

Cummings, SR .

OSTEOPOROSIS INTERNATIONAL, 2005, 16 (07) :842-848

[9]

Official Positions of the International Society for Clinical Densitometry.[J].Edward S. Leib;E. Michael Lewiecki;Neil Binkley;Ronald C. Hamdy.Journal of Clinical Densitometry.2004, 1

[10]

Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study [J].

Iki, M ;

Akiba, T ;

Matsumoto, T ;

Nishino, H ;

Kagamimori, S ;

Kagawa, Y ;

Yoneshima, H .

OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :981-991

← 1 2 →